Opinion|Videos|February 25, 2025
Reflecting on 2024 in CLL: Key Advances and Looking Ahead to 2025
Panelists discuss how the remarkable evolution of chronic lymphocytic leukemia (CLL) therapy over recent years has dramatically improved patient outcomes through the development of targeted therapies like Bruton tyrosine kinase (BTK) inhibitors and BCL2 inhibitors while expressing excitement about emerging approaches like BTK degraders, noncovalent BTK inhibitors, and cellular therapies that promise to further advance the field in 2025 and beyond.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What accomplishments in CLL are you most proud of either in frontline setting or in the relapsed/refractory space? Which developments stand out as pivotal in shaping clinical practice?
- What are you most excited about in 2025? What areas are primed for significant progress? What do you hope to achieve in the coming year?
Advertisement
Related to this article
Experts break down key melanoma data and trends from the 2026 ESMO Congress.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.
Durvalumab plus BCG is now an approved first-line option for high-risk NMIBC, but better BCG delivery and biomarker-guided selection should shape its use.
The FDA has approved amivantamab and hyaluronidase-lpuj for metastatic head and neck squamous cell carcinoma.
A UCLA-led study suggests routine mammograms or other breast imaging may not benefit women after double mastectomy for DCIS.
Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.
Are we ready to “take that fork in the road” and move palliative/supportive care into routine cancer care?
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
3
Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL
4
Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
5